Announcements - OBI Pharma 台灣浩鼎

2017.Oct.06

USPTO Approved the Patent Application for OBI-888 "Antibodies, pharmaceutical compositions and uses thereof"

2017.Sep.25

Contract Signing with Pharmacore for the Contract Manufacturing of OBI-858

2017.Aug.11

Announcement on Change of the Acting Spokesperson

2017.Aug.11

Announcement on Change of the Head of Finance and Accounting

2017.Jul.21

OBI Received a Civil Complaint from Taiwan Shilin District Court

2017.Jul.12

Clarification on the news article by China Times

2017.Jun.29

Clarification on the news article by Commercial Times

2017.Jun.28

Important Resolutions of AGM 2017

2017.Jun.11

Supplemental information on the approved application of Phase III clinical trial of OBI-822, the novel breast cancer drug, in China, US, and the EU

2017.Jun.01

OBI Pharma Announces Acquisition of the Novel First-in-class Anti-Cancer Drug OBI-3424 from Threshold Pharmaceuticals to be Developed as Potential Anti-Cancer Therapy for Cancers with High AKR1C3

News

Latest News

Events

Latest events